The National Lung Matrix Trial is the largest precision medicine trial in non-small cell lung cancer globally, testing a wide-range of therapies tailored specifically to target key genetic changes in cancer cells.
Find out more about the trial and how to get involved.
Find out more about the trial design and access our publications.
Access information for hospitals and download current trial documentation.
Stratified Medicine Programme 2
Cancer Research UK’s Stratified Medicine Programme 2 provides national genomic pre-screening for patients with Non-Small Cell Lung cancer, and is required to determine patient molecular eligibility for the National Lung Matrix Trial.
Find out more
Also in 'National Lung Matrix Trial'
Gary Middleton - Precision Medicine Trials in Non-Small Cell Lung Cancer - PMWC UK 2015, Oxford
ESMO 2014: The ‘National Lung Matrix’ trial – a new strategy for cancer drug research
ECMC Announcement - SMP2 and NLMT programme updates
In this post, Jane Hair, a biobanker who works at the biorepository unit in Glasgow, and is involved in the National Lung Matrix Trial, shares what her job involves.
Over 1,800 patients have been screened through the Stratified Medicine Programme Phase 2 (SMP2), with the 100th patient being recruited to the National Lung Matrix Trial (NLMT) in November 2016.
MORE NEWS STORIES